Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing.

ABSTRACT:

Background

Targeted therapies including monoclonal antibodies and small molecule inhibitors have dramatically changed the treatment of cancer over past 10 years. Their therapeutic advantages are more tumor specific and with less side effects. For precisely tailoring available targeted therapies to each individual or a subset of cancer patients, next-generation sequencing (NGS) has been utilized as a promising diagnosis tool with its advantages of accuracy, sensitivity, and high throughput.

Methods

We developed and validated a NGS-based cancer genomic diagnosis targeting 115 prognosis and therapeutics relevant genes on multiple specimen including blood, tumor tissue, and body fluid from 10 patients with different cancer types. The sequencing data was then analyzed by the clin

SUBMITTER: Xie J 

PROVIDER: S-EPMC4867560 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature